ClinicalTrials.gg
Not yet recruitingNCT07287839Updated Dec 18, 2025

Parcel-guided rTMS for Major Depressive Disorder

A Phase 2 interventional study of Accelerated rTMS and Parcel-guided Accelerated rTMS in Treatment Resistant Depression (TRD), sponsored by Soterix Medical. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Soterix Medical · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Study comparing standard repetitive transcranial magnetic stimulation (rTMS) for Depression to a novel targeting approach using brain surface parcellation to locate a specific brain target.

Read the detailed description

Standard rTMS treatment often uses the "Beam-F3" targeting approach to locate a brain region known as the left dorsolateral prefrontal cortex (lDLPFC). However, Beam-F3 does not take into account interindividual variation in brain anatomy. Researchers as Columbia University have found a more accurate and personalized approach that uses MRI-based brain surface parcellation to locate the specific subregion of the lDLPFC most ideal for rTMS treatment. Our study is comparing standard rTMS (Beam-F3) to parcel-guided rTMS for patients with treatment resistant depression.

02

Conditions studied

  • Treatment Resistant Depression (TRD)

Keywords

  • rTMS
  • TMS
  • parcel-guided
  • beam-F3
03

In context

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

This study's planned enrollment of 60 is close to the median of 58 across 373 interventional studies indexed under Depressive Disorder, Treatment-Resistant.

Browse Depressive Disorder, Treatment-Resistant studies →

Lead sponsor

Soterix Medical is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of major depressive disorder confirmed using the Mini International Neuropsychiatric Interview (MINI30) Axis 1 and mood modules
  • Treatment-resistant MDD during the current major depressive episode documented in the MGH Antidepressant Treatment History Questionnaire (ATRQ31), which will be defined as being non-responders (less than 50% of symptom improvement) to two or more depression treatment trials of adequate dose and duration as defined by the MGH ATRQ.
  • At least moderate depression severity, operationalized as Montgomery-Asberg Depression Rating Scale (MADRS) score ≥ 20

Exclusion criteria

Exclusion Criteria:

  • Ever met criteria for a psychotic disorder (Sz, SzAff, Bipolar disorder)
  • Anorexia nervosa or bulimia nervosa within the last year
  • Unstable medical condition by history, physical exam or laboratory results
  • Currently pregnant or breastfeeding women; fecund women not using adequate methods or with plan to become pregnant
  • to MRI (based on metal screening form)
  • Meets criteria for claustrophobia
  • Recent drug or alcohol use disorder with specifier of moderate or severe within 6 months, or mild within 2 months; or lifetime history of IV drug use A- ctively suicidal, as defined by expressive ideation with a plan or with suicidal ideation that requires immediate medical or treatment intervention.
  • Neurological or neuromuscular disorder
  • Requires medications for a general medical condition that contraindicate the TMS treatment
  • Prior non-response to ECT, vagal nerve stimulation (VNS) or deep brain stimulation (DBS)
  • History of ketamine treatment within 6 months
  • History of monoamine oxidase inhibitor (MAOI) within the past month
  • Lacks capacity to consent
  • Taking medications that increase the risk of seizures.
  • For patients on permitted concomitant psychotropic agents (antidepressants, anticonvulsants, benzodiazepines, hypnotics, opiates, triiodothyronine (T3), modafinil, psychostimulants, buspirone, melatonin, omega-3 fatty acids, folate, l-methylfolate, s-adenosyl methionine, lithium) dosing must be stable for at least four weeks prior to study entry and patients must agree to continue at the same dose during the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Standard rTMS

    rTMS using standard targeting (Beam-F3) will be delivered

    Device: Accelerated rTMS

  • Experimental
    Parcel-guided rTMS

    rTMS will be delivered using brain-surface parcellation targeting

    Device: Parcel-guided Accelerated rTMS

Interventions

  • DeviceAccelerated rTMS

    rTMS targeting will be done using the standard Beam-F3 targeting method. Treatment will be delivered in an accelerated schedule with 50 treatment session over 5 days.

  • DeviceParcel-guided Accelerated rTMS

    rTMS targeting will be done using brain surface parcellation. Treatment will be delivered in an accelerated schedule with 50 treatment sessions over 5 days.

06

What researchers measure

Primary outcomes

  1. Montgomery-Asberg Depression Rating Scale (MADRS)

    Depression severity scale with a score ranging from 0 to 60 where a higher score indicates greater severity of symptoms.

    Time frame: Baseline and at end of Week 1

Secondary outcomes

  1. Hamilton Depression Rating Scale Anxiety Somatization Subscale (HAMD-AS)

    six-item subscale of psychiatric disorder severity where a score is given between 0 and 18 and a higher score indicates greater severity of symptoms

    Time frame: Baseline and at Week 1

  2. Side-effect form (SEF)

    Clinician-rated simple form to document the onset, course, severity, and causality of adverse events

    Time frame: Daily from Baseline until Week 1

  3. Columbia suicide severity rating scale (C-SSRS)

    Rating scale for suicidal ideation with scores ranging from 0 to 5 where a higher score indicates greater severity of symptoms

    Time frame: Baseline and Week 1

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Moreno-Ortega M, Kangarlu A, Lee S, Perera T, Kangarlu J, Palomo T, Glasser MF, Javitt DC. Parcel-guided rTMS for depression. Transl Psychiatry. 2020 Aug 12;10(1):283. doi: 10.1038/s41398-020-00970-8. PubMed 32788580 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Jun 2028, 29 months later.

Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's planned 29 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2025
First posted
Dec 17, 2025
StartEst.
Dec 15, 2025
Primary completionEst.
Jun 1, 2028
CompletionEst.
Jun 15, 2028
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07287839
Lead sponsor
Soterix Medical
Collaborators
Columbia University
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Dec 15, 2025 (estimated)
Primary completion
Jun 1, 2028 (estimated)
Completion
Jun 15, 2028 (estimated)
Last update
Dec 18, 2025

Study contacts

Yishai Valter, MS
Contact
trials@soterixmedical.com
888-990-8327
Abhishek Datta, PhD
principal investigator · Soterix Medical, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion